Human immunodeficiency virus negative, immunocompetent primary effusion lymphoma with a complete response on R-miniCHOP

人类免疫缺陷病毒阴性、免疫功能正常的原发性渗出性淋巴瘤,接受R-miniCHOP方案治疗后获得完全缓解。

阅读:1

Abstract

Primary effusion lymphoma (PEL) is a rare kind of extranodal non-Hodgkin large B-cell lymphoma that develops in the liquid phase in serous membrane-lined body cavities (perineum, pericardium, and pleura) without tumor masses. Kaposi sarcoma-associated human herpesvirus 8 (HHV8) is essential in establishing a diagnosis of PEL. An 84-year-old male with a past medical history of testicular cancer in his 40s presented with a chief complaint of shortness of breath which was attributed to a left pleural effusion. The flow cytometry indicated 32% small T lymphocytes (cluster of differentiation [CD]4: CD8 = 4.0:1), 9.0% small B lymphocytes without surface light chain expression, and 16% unknown phenotypic large cells. The cell block demonstrated large atypical lymphocytes with irregular nuclear membranes and coarse chromatin. The cells exhibited prominent nucleoli and relatively basophilic, abundant amphophilic cytoplasm. Multinucleated and Reed-Sternberg-like cells were also seen. We performed a panel of immunomarkers including HHV8 and ALK1. The tumor cells were positive for CD45, CD20, and HHV8 and negative for all other markers. Based on morphologic and immunophenotypical features, a diagnosis of PEL is rendered. Positron emission tomography/computed tomography showed an absence of fluorodeoxyglucose uptake in the lymph nodes and the spleen. Given his age, the patient started on treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone at reduced doses (R-miniCHOP) and had a complete response. To our knowledge, there are no other reported cases of complete remission following an attenuated R-miniCHOP protocol in this clinical scenario.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。